OncoSenX is pioneering a novel approach to cancer therapy that focuses on targeting solid tumors through a combination of a non-toxic Proteo-Lipid Vehicle (PLV) and a highly specific DNA payload. The PLV serves as an efficient delivery system for plasmid DNA, which encodes an inducible death protein activated in cancer cells exhibiting transcriptional activity for p53. This targeted mechanism allows for the induction of apoptosis in cancerous cells while sparing adjacent healthy cells, thereby minimizing side effects typically associated with conventional cancer treatments. The technology also incorporates the use of logic gates (IF/OR/AND) to enhance precision in targeting specific cell populations based on their genetic activity.

The safety profile of OncoSenX's PLV has been rigorously evaluated, demonstrating a lack of immunogenic response even in immune-competent models, and showing non-toxicity at doses significantly higher than expected therapeutic levels in both rodents and non-human primates. This innovative approach not only aims to improve the efficacy of cancer treatments but also seeks to establish a less invasive and more precise intervention strategy. By leveraging genetic information, OncoSenX is positioned to contribute significantly to the next generation of cancer therapies, focusing on targeted interventions that promise to enhance patient outcomes.

United States

OncoSenX is a developer of transient gene therapies designed for solid tumors. The company is headquartered in Seattle, Washington and is focused on developing tumor-killing therapeutics using genetic information.

Cancer

OncoSenX

OncoSenX

Company Details